Survodutide (10mg)
Survodutide (BI 456906) is an investigational GLP-1/Glucagon dual agonist for weight loss and metabolic liver disease. Reconstitute with 2.0 mL bacteriostatic water for a concentration of 5 mg/mL (50 mcg per 1 unit).
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Survodutide acts as a dual agonist: GLP-1 action reduces appetite and slows gastric emptying, while Glucagon action increases thermogenesis, lipolysis, and energy expenditure. This combination has been associated with greater weight loss (12.5–14.9% at 46 weeks in Phase 2) compared to GLP-1 mono-agonists. Dose-dependent weight loss is described in available clinical data.
Quick Start
- Reconstitution: Add 2.0 mL bacteriostatic water → 5 mg/mL.
- Weekly Range: 0.6–6.0 mg once weekly (10–12 week progressive titration).
- Storage: Lyophilized ≤−20 °C; reconstituted 2–8 °C, protect from light.
Progressive Titration (2 mL = 5 mg/mL)
Route: Subcutaneous injection | Frequency: Once weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 0.6 mg | 12 Units (0.12 mL) |
| Weeks 3–4 | 1.2 mg | 24 Units (0.24 mL) |
| Weeks 5–6 | 1.8 mg | 36 Units (0.36 mL) |
| Weeks 7–8 | 2.4 mg | 48 Units (0.48 mL) |
| Weeks 9–10 | 3.6 mg | 72 Units (0.72 mL) |
| Weeks 11–12 | 4.8 mg | 96 Units (0.96 mL) |
| Week 13+ | 6.0 mg | 2 × 60 Units (0.60 mL) |
Titrate every 2 weeks by +0.6 mg. *The 6.0 mg dose (120 units / 1.20 mL) exceeds a 100-unit syringe—use a 1 mL Luer-lock syringe or split into 2 injections.
Related compounds
Reconstitution Steps
- Wipe vial stoppers with an alcohol pad.
- Draw 2.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial; avoid foaming.
- Gently swirl until fully dissolved (do not shake vigorously).
- Note the date; refrigerate (2–8 °C), protecting from light.
Protocol Overview
- Objective: Metabolic improvement and weight management via dual GLP-1/Glucagon agonism.
- Schedule: Weekly subcutaneous injections for 12–16+ weeks.
- Storage: Lyophilized frozen; reconstituted refrigerated; protect from light.
Dosing Protocol
- Initiation: 0.6 mg weekly.
- Escalation: Increase by +0.6 mg every 2 weeks as tolerated.
- Target: 4.8–6.0 mg weekly by week 11–13.
- Frequency: Once weekly (subcutaneously).
- Cycle: 12–16 weeks minimum; Phase 3 clinical trials: 48–72 weeks.
- Break between cycles: Post-cycle, a pause of 4–8 weeks is recommended. Survodutide (a GLP-1/glucagon dual agonist) requires sufficient clearance before a new cycle.
Washout & Cycle Restart
When can I restart?
Post-cycle, a pause of 4–8 weeks is recommended. Survodutide (a GLP-1/glucagon dual agonist) requires sufficient clearance before a new cycle.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: ≤−20 °C in dry, dark conditions.
- Reconstituted: 2–8 °C; protect from light; avoid freeze-thaw cycles.
- Allow vials to reach room temperature before opening.
Important Notes
- Survodutide is currently in Phase 3 clinical trials.
- Glucagon agonism may increase glucose—monitor.
- Contraindicated in MTC or MEN2 family history.
- Progressive titration is critical for minimizing GI side effects.
Potential Benefits & Side Effects
Potential Benefits:
- Clinical weight loss data (12.5–14.9% in Phase 2 studies).
- Increased energy expenditure via Glucagon agonism.
- Reduction in visceral fat.
- Improvement in lipid profile.
- Potential hepatoprotective action (NASH/MAFLD).
- MASH (2026): Phase 2 data reported up to 83% MASH resolution without worsening of fibrosis at 4.8–6.0 mg weekly doses.
- New Phase 3 (2025–2026): ~19% weight loss at 46 weeks in international cohort analyses.
Potential Side Effects:
- Nausea (more frequent due to Glucagon action).
- Vomiting.
- Diarrhea.
- Decreased appetite.
- Transient increase in heart rate.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Potential thyroid C-cell risk
GLP-1/Glucagon dual agonist — class-effect risk of C-cell tumors.
📄 Phase 2 MASH Trial — Lancet 2024References
- Lancet Diabetes & Endocrinology (2023) — Survodutide (BI 456906) in type 2 diabetes and obesity — phase 2
View Source - The Lancet (2018) — MEDI0382, GLP-1/Glucagon dual agonist — proof of concept
View Source - NEJM MASH Phase 2 (2024) — Survodutide for MASH: up to 83% MASH resolution without worsening of fibrosis at 48 weeks.
View Source - Boehringer Ingelheim Phase 3 update (2026) — SYNCHRONIZE phase 3 in obesity and MASH — 2025–2026 developments.
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
MASH / Obesity
MASH / Obesity
Phase III clinical trials
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →